Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy
V Shahabi, MA Postow, D Tuck… - American journal of …, 2015 - journals.lww.com
A clear contribution of the immune system to eradication of tumors has been supported by
recent developments in the field of immunotherapy. Durable clinical responses obtained
after treatment with immunomodulatory agents such as ipilimumab (Yervoy) and anti-PD-1
antibody (BMS-936558), have established that harnessing the immune response against
chemoresistant tumors can result in their complete eradication. However, only a subset of
patients benefit from these therapeutic approaches. Accumulating evidence suggests that …
recent developments in the field of immunotherapy. Durable clinical responses obtained
after treatment with immunomodulatory agents such as ipilimumab (Yervoy) and anti-PD-1
antibody (BMS-936558), have established that harnessing the immune response against
chemoresistant tumors can result in their complete eradication. However, only a subset of
patients benefit from these therapeutic approaches. Accumulating evidence suggests that …